Equities Analysts Set Expectations for ABEO Q1 Earnings

Abeona Therapeutics Inc (NASDAQ:ABEO) – Equities researchers at HC Wainwright decreased their Q1 2025 earnings estimates for Abeona Therapeutics in a report released on Monday, March 24th. HC Wainwright analyst R. Selvaraju now expects that the biopharmaceutical company will earn ($0.36) per share for the quarter, down from their prior forecast of ($0.34). HC Wainwright currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($1.16) per share. HC Wainwright also issued estimates for Abeona Therapeutics’ Q3 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.13) EPS and FY2025 earnings at ($1.11) EPS.

Abeona Therapeutics (NASDAQ:ABEO) last announced its quarterly earnings data on Thursday, March 20th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.19.

A number of other equities analysts also recently commented on ABEO. StockNews.com upgraded Abeona Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday. Oppenheimer assumed coverage on Abeona Therapeutics in a report on Wednesday, March 5th. They set an “outperform” rating and a $16.00 price target on the stock. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, Abeona Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $17.50.

Abeona Therapeutics Trading Down 0.2 %

Shares of Abeona Therapeutics stock opened at $4.99 on Wednesday. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.12 and a quick ratio of 6.12. The stock’s 50 day simple moving average is $5.43 and its 200-day simple moving average is $5.82. The stock has a market cap of $216.92 million, a P/E ratio of -1.86 and a beta of 1.79. Abeona Therapeutics has a 1-year low of $3.05 and a 1-year high of $8.45.

Institutional Trading of Abeona Therapeutics

Institutional investors have recently made changes to their positions in the company. Adage Capital Partners GP L.L.C. increased its stake in Abeona Therapeutics by 20.1% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 3,902,360 shares of the biopharmaceutical company’s stock worth $21,736,000 after acquiring an additional 652,366 shares during the last quarter. Western Standard LLC grew its holdings in shares of Abeona Therapeutics by 22.8% during the 4th quarter. Western Standard LLC now owns 2,084,418 shares of the biopharmaceutical company’s stock worth $11,610,000 after purchasing an additional 386,321 shares during the period. 683 Capital Management LLC increased its position in shares of Abeona Therapeutics by 17.3% during the 4th quarter. 683 Capital Management LLC now owns 791,845 shares of the biopharmaceutical company’s stock worth $4,411,000 after purchasing an additional 116,845 shares during the last quarter. Citigroup Inc. raised its holdings in Abeona Therapeutics by 10.1% in the 3rd quarter. Citigroup Inc. now owns 616,668 shares of the biopharmaceutical company’s stock valued at $3,897,000 after buying an additional 56,332 shares during the period. Finally, Geode Capital Management LLC lifted its position in Abeona Therapeutics by 21.7% in the third quarter. Geode Capital Management LLC now owns 465,317 shares of the biopharmaceutical company’s stock valued at $2,942,000 after buying an additional 83,050 shares during the last quarter. Hedge funds and other institutional investors own 80.56% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.